RecruitingNot ApplicableNCT07009418

Smart Angioplasty Research Team-Coronary CT Angiography Versus Standard Care as Follow-up Strategies in High-Risk Patients After PCI (SMART-CARE)

Coronary Computed Tomography Angiography Versus Standard Care in High-Risk Patients After Percutaneous Coronary Intervention


Sponsor

Samsung Medical Center

Enrollment

3,500 participants

Start Date

Oct 2, 2025

Study Type

INTERVENTIONAL

Conditions

Summary

The aim of the SMART-CARE trial is to compare clinical outcomes between coronary CT angiography (CCTA) versus standard care as follow-up strategies in high-risk patients after percutaneous coronary intervention (PCI).


Eligibility

Min Age: 19 Years

Inclusion Criteria10

  • ① Patients aged 19 years old
  • ② Patients who underwent successful PCI with one or more contemporary drug-eluting stents (stent diameter ≥3mm) or drug-coated balloons.
  • ③ Patients must have at least one of the following criteria of complex coronary artery lesions or high-risk clinical characteristics:
  • A. Complex coronary artery lesions:
  • i. True bifurcation lesion (Medina 1,1,1/1,0,1/0,1,1) with side branch ≥2.5mm size ii. Chronic total occlusion (≥3 months) as target lesion iii. PCI for unprotected left main (LM) disease (LM ostium, body, distal LM bifurcation including non-true bifurcation) iv. Long coronary lesions (used stents or drug-coated balloons ≥38 mm in length) v. Multi-vessel PCI (≥2 major epicardial coronary arteries treated at one PCI session) vi. Multiple devices needed (≥3 more stents or drug-coated balloons per patient) vii. In-stent restenosis lesion as target lesion viii. Severely calcified lesion (encircling calcium in angiography) ix. Left anterior descending (LAD), left circumflex artery (LCX), and right coronary artery (RCA) ostial lesion
  • B. High-risk clinical characteristics:
  • i. Acute myocardial infarction (ST-elevation myocardial infarction \[MI\] or non-ST-elevation MI) with or without cardiogenic shock (SCAI Classification ≥C) at presentation ii. Diabetes mellitus which requires medical treatment (oral hypoglycemic agents or insulin) iii. End-stage renal disease under dialysis iv. Combined vascular disease other than coronary artery disease
  • Peripheral artery occlusive disease which is defined as A. Previous aorto-femoral bypass surgery, limb bypass surgery, or percutaneous transluminal angioplasty revascularization of the iliac, or infra-inguinal arteries, or B. Previous limb or foot amputation for arterial vascular disease, or C. History of intermittent claudication and one or more of the following: 1) An ankle/arm blood pressure (BP) ratio < 0.90, or 2) Significant peripheral artery stenosis (≥50%) documented by angiography, or by duplex ultrasound, or D. Previous carotid revascularization or asymptomatic carotid artery stenosis ≥50% as diagnosed by duplex ultrasound or angiography.
  • Thoracoabdominal aortic disease which is defined as A. Documented thoracoabdominal aortic aneurysm by duplex ultrasound, angiography, or computed tomography angiography B. Previous endovascular or surgical treatment for thoracoabdominal aortic aneurysm
  • ④ Subject who can verbally confirm understandings of risks, benefits and surveillance strategy alternatives of receiving CCTA and he/she or his/her legally authorized representative provides written informed consent prior to any study related procedure.

Exclusion Criteria3

  • ① Advanced chronic kidney disease (Creatinine clearance <30 ml/min/1.73 m2) not on dialysis
  • Known true anaphylaxis to contrast medium (not allergic reaction but anaphylactic shock)
  • Pregnancy or breast feeding ④ Non-cardiac co-morbid conditions are present with life expectancy <1 year or that may result in protocol non-compliance (per site investigator's medical judgment) ⑤ Unwillingness or inability to comply with the procedures described in this protocol.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DIAGNOSTIC_TESTCoronary CT Angiography (CCTA)

In the surveillance by CCTA group, patients will be evaluated by CCTA at 1 year from index hospitalization. CCTA will be done according to current acquisition guidelines. Downstream management according to the results from CCTA will be performed under recommendations from current guidelines.


Locations(22)

SoonChunHyang University Hospital Bucheon

Bucheon-si, South Korea

Keimyung University Dongsan Medical Center

Daegu, South Korea

Kyungpook National University Hospital

Daegu, South Korea

Chonnam National University Hospital, Chonnam National University Medical School

Gwangju, South Korea

Chung-Ang University Gwangmyeong Hospital

Gwangmyeong, South Korea

Inje University College of Medicine, Ilsan Paik Hospital

Ilsan, South Korea

Gachon University Gil Medical Center

Incheon, South Korea

Kwandong University Intl. ST. Mary's Hospital

Incheon, South Korea

Jeonbuk National University Hospital

Jeonju, South Korea

Gyeongsang National University Hospital

Jinju, South Korea

Seoul National University Bundang Hospital

Seongnam-si, South Korea

Samsung Medical Center

Seoul, South Korea

Chung-Ang University Hospital, Chung-Ang University College of Medicine

Seoul, South Korea

Ewha Womans University Seoul Hospital

Seoul, South Korea

Hanyang University Seoul Hospital, College of Medicine, Hanyang University

Seoul, South Korea

Korea University Anam Hospital

Seoul, South Korea

Korea University Kuro Hospital

Seoul, South Korea

Kyung Hee University Medical Center

Seoul, South Korea

Seoul National University Boramae Medical Center

Seoul, South Korea

Ajou University Hospital

Suwon, South Korea

Catholic University of Korea Uijeongbu St. Mary's Hospital

Uijeongbu-si, South Korea

Wonju Severance Christian Hospital

Wŏnju, South Korea

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07009418


Related Trials